External Evaluation of a Novel Prostate Cancer Risk Calculator (ProstateCheck) Based on Data from the Swiss Arm of the ERSPC.
- Poyet C Department of Urology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
- Wettstein MS Department of Urology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
- Lundon DJ Department of Urology, Mater Misericordiae University Hospital, Dublin, Ireland.
- Bhindi B Department of Surgery, Division of Urology, University Health Network, University of Toronto, Toronto, Ontario, Canada.
- Kulkarni GS Department of Surgery, Division of Urology, University Health Network, University of Toronto, Toronto, Ontario, Canada.
- Saba K Department of Urology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
- Sulser T Department of Urology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
- Vickers AJ Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
- Hermanns T Department of Urology, University Hospital Zürich, University of Zürich, Zürich, Switzerland. Electronic address: thomas.hermanns@usz.ch.
- 2016-05-19
Published in:
- The Journal of urology. - 2016
biopsy
decision support techniques
nomograms
prostate-specific antigen
prostatic neoplasms
Aged
Biopsy
Humans
Male
Middle Aged
Prostatic Neoplasms
Retrospective Studies
Risk Assessment
Switzerland
English
PURPOSE
We externally validated a novel prostate cancer risk calculator based on data from the Swiss arm of the ERSPC and assessed whether the risk calculator (ProstateCheck) is superior to the PCPT-RC and SWOP-RC in an independent Swiss cohort.
MATERIALS AND METHODS
Data from all men who underwent prostate biopsy at an academic tertiary care center between 2004 and 2012 were retrospectively analyzed. The probability of having any prostate cancer or high grade prostate cancer (Gleason score 7 or greater) on prostate biopsy was calculated using the ProstateCheck. Risk calculator performance was assessed using calibration and discrimination, and additionally compared with the PCPT-RC and SWOP-RC by decision curve analyses.
RESULTS
Of 1,615 men 401 (25%) were diagnosed with any prostate cancer and 196 (12%) with high grade prostate cancer. Our analyses of the ProstateCheck-RC revealed good calibration in the low risk range (0 to 0.4) and moderate overestimation in the higher risk range (0.4 to 1) for any and high grade prostate cancer. The AUC for the discrimination of any prostate cancer and high grade prostate cancer was 0.69 and 0.72, respectively, which was slightly but significantly higher compared to the PCPT-RC (0.66 and 0.69, respectively) and SWOP-RC (0.64 and 0.70, respectively). Decision analysis, taking into account the harms of transrectal ultrasound measurement of prostate volume, showed little benefit for ProstateCheck-RC, with properties inferior to those of the PCPT-RC and SWOP-RC.
CONCLUSIONS
Our independent external evaluation revealed moderate performance of the ProstateCheck-RC. Its clinical benefit is limited, and inferior to that of the PCPT-RC and SWOP-RC.
We externally validated a novel prostate cancer risk calculator based on data from the Swiss arm of the ERSPC and assessed whether the risk calculator (ProstateCheck) is superior to the PCPT-RC and SWOP-RC in an independent Swiss cohort.
MATERIALS AND METHODS
Data from all men who underwent prostate biopsy at an academic tertiary care center between 2004 and 2012 were retrospectively analyzed. The probability of having any prostate cancer or high grade prostate cancer (Gleason score 7 or greater) on prostate biopsy was calculated using the ProstateCheck. Risk calculator performance was assessed using calibration and discrimination, and additionally compared with the PCPT-RC and SWOP-RC by decision curve analyses.
RESULTS
Of 1,615 men 401 (25%) were diagnosed with any prostate cancer and 196 (12%) with high grade prostate cancer. Our analyses of the ProstateCheck-RC revealed good calibration in the low risk range (0 to 0.4) and moderate overestimation in the higher risk range (0.4 to 1) for any and high grade prostate cancer. The AUC for the discrimination of any prostate cancer and high grade prostate cancer was 0.69 and 0.72, respectively, which was slightly but significantly higher compared to the PCPT-RC (0.66 and 0.69, respectively) and SWOP-RC (0.64 and 0.70, respectively). Decision analysis, taking into account the harms of transrectal ultrasound measurement of prostate volume, showed little benefit for ProstateCheck-RC, with properties inferior to those of the PCPT-RC and SWOP-RC.
CONCLUSIONS
Our independent external evaluation revealed moderate performance of the ProstateCheck-RC. Its clinical benefit is limited, and inferior to that of the PCPT-RC and SWOP-RC.
- Language
-
- English
- Open access status
- green
- Identifiers
-
- DOI 10.1016/j.juro.2016.05.081
- PMID 27188476
- Persistent URL
- https://sonar.ch/global/documents/236524
Statistics
Document views: 26
File downloads:
- fulltext.pdf: 0